Local Institution

Pittsburgh, Pennsylvania 15232-1305

0 studies enrolling now · 33 studies all time

What they study most

Advanced Cancer, Bipolar I Disorder, Bladder Cancer, Bladder Neoplasms, Blast Crisis, Breast Cancer, Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Type 2, Essential Thrombocythemia, Focal Segmental Glomerulosclerosis

Studies at this site

• A Study of Adjunctive Aripiprazole in Participants With Major Depressive Disorder — Completed
• Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003) — Completed
• A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread — Completed
• An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma — Completed
• An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed — Stopped early
• Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) — Completed
• Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer — Completed
• A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease — Completed
• Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC) — Completed
• A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc) — Withdrawn before enrolling
• A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma — Completed
• A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer — Completed
• Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone — Completed
• Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise — Completed
• A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode — Completed
• A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder — Completed
• Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib — Completed
• Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy — Completed
• A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes — Completed
• Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia — Completed
• Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients — Completed
• Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia — Completed
• Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris — Completed
• Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes — Completed
• A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics — Completed
• Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone — Completed
• Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate — Completed
• Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia — Completed
• A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies — Stopped early
• BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery — Completed
• Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer — Stopped early
• Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium — Completed
• A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy — Stopped early